With the finding that histone deacetylase inhibitors may be promising therapeutics, we performed a multi-omics approach to determine the effect of HDAC inhibitors on the chromatin structure of IDH1 mutant gliomas. The gene discussed is HDAC9; the disease is central nervous system cancer.